Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs for the treatment of serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study to evaluate the therapeutic benefit of blisibimod injections in patients with lupus.
The study enrolled 547 patients in 11 countries and 72 clinical sites around the world to test the efficacy, safety and tolerability of blisibimod.
Consistent with previous clinical studies, the on-going PEARL-SC study indicates that weekly and monthly doses of blisibimod significantly reduced B-cells, data which is of value because elevations in these cells have been associated with an increased risk of disease activity in lupus patients.
“We believe reductions of B-cells in the PEARL-SC study will correlate to a reduction in disease activity in patients treated with blisibimod,” Colin Hislop, MD, chief medical officer and senior vice president of Anthera stated in the press release. “This analysis demonstrates that the selected weekly and monthly blisibimod doses resulted in an appropriate biological response. If confirmed with positive clinical outcomes from the PEARL-SC study, these data will provide guidance for the design of our phase 3 clinical studies and allow us to differentiate blisibimod from other available BAFF inhibitors for the treatment of lupus.”
Anthera said it expects final results from the PEARL-SC clinical study in the second quarter of 2012.
For more information visit www.anthera.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment